Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma
Uloženo v:
| Název: | Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma |
|---|---|
| Autoři: | Harris, A, Jonescu-Cuypers, Christian Paul, Kagemann, L, Nowacki, E A, Garzozi, H, Cole, C, Martin, B |
| Zdroj: | American Journal of Ophthalmology, Vol. 132, No 4 (2001) pp. 490-495 |
| Informace o vydavateli: | Elsevier BV, 2001. |
| Rok vydání: | 2001 |
| Témata: | Indocyanine Green, Retinal Artery, Ciliary Arteries/diagnostic imaging/physiopathology, Adrenergic beta-Antagonists, Sulfonamides/administration & dosage/therapeutic use, Visual Acuity, Eye, Ciliary Arteries, Tonometry, Timolol/administration & dosage/therapeutic use, Intraocular Pressure/drug effects, Ophthalmic Artery, 03 medical and health sciences, 0302 clinical medicine, Drug Therapy, Double-Blind Method, Ocular, Eye/blood supply, Open-Angle/drug therapy/physiopathology, Laser-Doppler Flowmetry, Humans, Fluorescein Angiography, Antihypertensive Agents, Intraocular Pressure, Ultrasonography, Sulfonamides, Cross-Over Studies, Ophthalmic Artery/diagnostic imaging/physiopathology, Glaucoma, 3. Good health, Ophthalmoscopy, Retinal Artery/diagnostic imaging/physiopathology, Adrenergic beta-Antagonists/administration & dosage/therapeutic use, Regional Blood Flow, Combination, Thiophenes/administration & dosage/therapeutic use, Drug Therapy, Combination, Ophthalmic Solutions, Antihypertensive Agents/administration & dosage/therapeutic use, Blood Flow Velocity, Glaucoma, Open-Angle |
| Popis: | Addition of dorzolamide to timolol in primary open-angle glaucoma shows augmented reduction of intraocular pressure. It is unknown as yet if addition of dorzolamide will alter hemodynamics.Fifteen patients with primary open-angle glaucoma were placed on a medication-dependent 1-week to 4-week washout that included maintenance on timolol. After washout, baseline measurements were taken (timolol). They were studied after a month on timolol or dorzolamide-timolol (Cosopt; Merck, Inc, Whitehouse Station, New Jersey), with the second drug preceded by another month of timolol maintenance and second baseline measurements. At each visit, visual function, intraocular pressure, and ocular hemodynamics were monitored, including indocyanine green and fluorescein angiography and color Doppler imaging.Cosopt significantly reduced intraocular pressure (14.7 to 13.4 mm Hg, P |
| Druh dokumentu: | Article |
| Popis souboru: | application/pdf |
| Jazyk: | English |
| ISSN: | 0002-9394 |
| DOI: | 10.1016/s0002-9394(01)01158-8 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/11589868 https://archive-ouverte.unige.ch/unige:154258 https://www.sciencedirect.com/science/article/abs/pii/S0002939401011588 https://pubmed.ncbi.nlm.nih.gov/11589868/ https://www.ncbi.nlm.nih.gov/pubmed/11589868 https://archive-ouverte.unige.ch/unige:154258 |
| Rights: | Elsevier TDM |
| Přístupové číslo: | edsair.doi.dedup.....a917af70383e40e5cddbbfdc1531bf91 |
| Databáze: | OpenAIRE |
| Abstrakt: | Addition of dorzolamide to timolol in primary open-angle glaucoma shows augmented reduction of intraocular pressure. It is unknown as yet if addition of dorzolamide will alter hemodynamics.Fifteen patients with primary open-angle glaucoma were placed on a medication-dependent 1-week to 4-week washout that included maintenance on timolol. After washout, baseline measurements were taken (timolol). They were studied after a month on timolol or dorzolamide-timolol (Cosopt; Merck, Inc, Whitehouse Station, New Jersey), with the second drug preceded by another month of timolol maintenance and second baseline measurements. At each visit, visual function, intraocular pressure, and ocular hemodynamics were monitored, including indocyanine green and fluorescein angiography and color Doppler imaging.Cosopt significantly reduced intraocular pressure (14.7 to 13.4 mm Hg, P |
|---|---|
| ISSN: | 00029394 |
| DOI: | 10.1016/s0002-9394(01)01158-8 |
Full Text Finder
Nájsť tento článok vo Web of Science